Citations

Clear

3042 citation(s) found for "Kumar, S".

Marine Microplastic Levels and the Prevalence of Cardiometabolic Diseases in US Coastline Counties
Makwana, Bhargav , Khadke, Sumanth , Kumar, Ashish , Nasir, Khurram , Wadhera, Rishi K. , Shah, Rikin , Sheth, Sudip , Kong, Yixin , Navas‐Acién, Ana , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Wadhera, Rishi K , Al-Kindi, Sadeer , Dani, Sourbha S , Ganatra, Sarju , Kumar, Ashish , Adamkiewicz, Gary , Dani, Sourbha S. , Moffatt‐Bruce, Susan D.

Mayo Clinic

Journal of the American Heart Association | June 18, 2025 | Volume: 14 | Issue: 13 | Pages: No page available

10.1161/jaha.124.039891 | PMID 40528809 Get It

Background Although micro‐ and nanoplastics are an emerging risk factor for the development of cardiovascular diseases, the association of marine microplastic levels (MMLs) with the burden of cardiometabolic diseases at a population level remains unexplored. We investigated the relationship between the mean microplastic concentration in ocean water within 200 nautical miles of the US coastline and the prevalence of type 2 diabetes, coronary artery disease, and stroke in nearby counties. Methods Microplastic concentration data within 200 nautical miles of the US coastline were geospatially analyzed to calculate mean MMLs. The coastal counties were stratified into 4 categories based on MMLs in the adjacent ocean water body: low, medium, high, or very high. The Behavioral Risk Factor Surveillance System 2019 to 2020 survey data were used to identify the prevalence of type 2 diabetes, coronary artery disease, and stroke in these counties. Univariate and population‐weighted multivariate quasi‐Poisson regression, adjusted for county‐level confounding variables, was used to evaluate the unadjusted and adjusted associations between disease prevalence and MMLs. Results The mean age of the population was 43±6 years. After adjusting for age, sex, physician access, and socioenvironmental vulnerabilities at the county level, counties with very high MMLs exhibited an 18%, 7%, and 9% higher adjusted prevalence of type 2 diabetes, coronary artery disease, and stroke, respectively, compared with those with low levels. Conclusion Marine microplastic levels were significantly associated with the prevalence of cardiometabolic diseases in coastal counties. Comprehensive studies at an individual level are needed to further investigate the health impacts of microplastic pollution.
The Association Between Physician Demographics on Patient Satisfaction Survey Results in Pediatrics: A Role for Implicit Bias?
Sas, David J. , Absah, Imad , Phelan, Sean M. , Joshi, Avni Y. , Creo, Ana L. , Kumar, Seema, Behl, Supriya, Hanson, Kristine T. , Phelan, S M , Behl, Supriya

Mayo Clinic

Clinical Pediatrics | June 16, 2025 | Volume: 64 | Issue: 11 | Pages: 1567-1580

10.1177/00099228251348311 | PMID 40522310 Get It

We assessed associations of pediatrician demographic characteristics with patient satisfaction (PS) scores. We performed a retrospective analysis of PS scores among pediatricians at a single academic institution and their associations with individual demographic features including gender, race, and geographic location of medical school education. We analyzed PS survey results for 153 pediatricians, 48.4% of whom were female. Males received higher scores in 4 out of 10 questions including “Likelihood of your recommending this care provider to others” ( P = .007). We observed similar findings for white pediatricians compared to Black, Indigenous, and People of Color (BIPOC) ( P = .033) and US medical school graduates compared to international school graduates ( P = .044). Overall, we observed that pediatricians who are female, BIPOC, or international medical school graduates receive lower PS scores than their counterparts. The impact of potential survey responder bias should be acknowledged when interpreting PS scores for pediatricians.
23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW)
Hartmann, S., Eich, Hans‐Theodor, Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, X., Wirth, A., Tsang, Rky, Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, A., Koenig, Julie L. , Casulo, Carla , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alex, Ricardi, U., Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Reeves, Michael A., Terezakis, S., Kirova, Youlia , Fergusson, Pamela, Lee, Denise , Ku, Matthew , Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Natkunam, Y., Kelly, Kara M. , Borchmann, Peter , Hoppe, R T, Binkley, Michael S., Hopkins, David , Ku, Matthew , Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, M., Hartmann, S., Savage, Kerry J. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Advani, Ranjana H. , Kumar, P., Dickinson, Michael , Tsang, R., Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Levis, Mario , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Fergusson, P., Northend, Michael , Hawkes, Eliza A. , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Salvaris, Ross , Hamad, Nada , Palese, M., Shankar, Ananth , Maurer, Matthew J. , Binkley, Michael S.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_23 Get It

In-hospital outcomes of early versus late transcatheter closure of patent ductus arteriosus in preterm infants
Elsisy, Mohamed, Nicholson, George T. , Stephens, Elizabeth H. , Sreenivasan, Gayathri , Elsisy, Mohamed F. , Sreenivasan, Gayathri , Gupta, Arpit Kumar

Mayo Clinic

Journal of Neonatal-Perinatal Medicine | June 16, 2025 | Volume: 19 | Issue: 1 | Pages: 22-27

10.1177/19345798251350986 | PMID 40521688 Get It

Background Transcatheter closure of patent ductus arteriosus (PDA) in small, premature infants is increasingly performed in the contemporary practice. Data regarding optimal timing of PDA closure are scarce. We therefore decided to compare morbidity and mortality of early and late device closure in preterm infants. Methods Hospitalizations of 166,583 newborn infants diagnosed with PDA were identified from the Kids’ Inpatient Database (KID) in 2009, 2012, 2016, and 2019. Of these, 299 preterm infants (gestational age (GA) ≤32 weeks, birth weight <1500 grams) underwent percutaneous PDA closure. Characteristics and periprocedural outcomes were compared between early (≤30 days) ( n = 120) and late PDA closure (>30 days) ( n = 179). Results Mean age (±standard deviation) for early PDA closure was 18.6 days ± 7 and 67.3 days ± 36.5 in late PDA closure. Comorbidities including respiratory distress syndrome/bronchopulmonary dysplasia, heart failure, and pulmonary hypertension were comparable between the two groups. There was no difference in mortality or referral for surgical ligation between early and late closure. Postprocedural vascular complications were low, but higher in patients with early PDA closure (3.3% vs 0%; p = 0.025). While the total length of hospital stay was longer in late PDA closure group (121.1 days ± 51.7 vs 81.5 days ± 48.8; p = <0.01), postprocedural length of stay was paradoxically longer in the early closure group (69 days ± 43.6 vs 57.5 days ± 43, p = 0.03). Conclusion There was no statistical difference in in-hospital mortality; however, there is a trend toward higher mortality in the early closure group. Major periprocedural complications are comparable between early and late PDA closure, except vascular complications that were higher with early PDA closure.
Hypercalcemia due to CYP24A1 variants in five unrelated patients: diagnostic and clinical considerations
Sarvaideo, Jenna , Colón-Franco, Jessica M , Kumar, Rajiv , Shaker, Joseph , Kumar, Rajiv

Mayo Clinic

JBMR Plus | June 13, 2025 | Volume: 9 | Issue: 9 | Pages: No page available

10.1093/jbmrpl/ziaf102 | PMID 40765620 Get It

Abstract Calcitriol-induced hypercalcemia is most frequently caused by granulomatous and inflammatory conditions such as sarcoidosis as well as lymphoma. Recently, pathogenic CYP24A1 variants resulting in inability of the 24-hydroxylase enzyme to deactivate 1,25(OH)2D has been found to be a cause of calcitriol-induced hypercalciuria and hypercalcemia in children and adults. Patients may present with hypercalcemia, suppressed PTH, hypercalciuria, and renal stones. We describe 4 young women and 1 man with calcitriol-associated hypercalcemia in whom pathogenic CYP24A1 variants were found to be the cause. In 2 of the 3 women who became pregnant, hypercalcemia worsened (the calcium was not checked during pregnancy in the third). Lactation was associated with worsened hypercalcemia in the 2 women who breast-fed. In the other woman who did not become pregnant, serum calcium levels varied from high normal to markedly elevated often without an explanation. The male patient was a middle-aged man with a long history of kidney stones and hypercalcemia as well as a family history of kidney stones. Gene sequencing confirmed that each patient had 2 variants in CYP24A1. We share 5 cases of a rare condition and further broaden the presentation of CYP24A1 variants to not only include worsening hypercalcemia in pregnancy, but also during lactation. Further calcium levels may vary markedly in patients with this condition. Physicians should consider pathogenic CYP24A1 variants in patients with unexplained calcitriol-associated hypercalcemia/hypercalciuria.
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Diamond, Benjamin , Poorebrahim, Mansour , Poos, Alexandra M. , Lee, Holly , Wiedmeier, Julia E. , Otteson, Gregory E., Tang, Hongwei , Fröhling, Stefan , Baertsch, Marc‐Andrea , Papadimitriou, Marios , Lemoine, Cendrine, Bergsagel, P. Leif , Kumar, Shaji , Weinhold, Niels , Bergsagel, P. Leif , Baughn, Linda, Wiedmeier-Nutor, J Erin, Durante, Michael , Otteson, Gregory, Rak, Alexey , Green, Damian J , Bergsagel, Leif, Braggio, Esteban , Kumar, Shaji K , Raab, Marc S , Maura, Francesco , Wiedmeier-Nutor, Julia E , Diamond, Benjamin T , Baughn, Linda B. , Kaddoura, Marcella , Durante, Michael , Jevremović, Dragan , Tang, Hongwei, Ziccheddu, Bachisio , Jelı́nek, Tomáš , Landgren, Ola , Neri, Paola , Braggio, Esteban , Raab, Marc S. , Fonseca, Rafaël , Bahlis, Nizar Jacques , Maura, Francesco

Mayo Clinic

Blood | June 10, 2025 | Volume: 146 | Issue: 13 | Pages: 1575-1585

10.1182/blood.2024028107 | PMID 40493883 Get It

Abstract Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can develop permanent resistance to anti-CD38 antibodies by acquiring genomic events leading to biallelic disruption of the CD38 gene locus. Here, we analyzed whole-genome and whole-exome sequencing data from patients 701 newly diagnosed MM, 67 patients at relapse with naivety to anti-CD38 antibodies, and 50 patients collected at relapse after anti-CD38 antibodies. We report a loss of CD38 in 10 of 50 patients (20%) after CD38 therapy, 3 of whom exhibited a loss of both copies. Two of these cases showed convergent evolution in which distinct subclones independently acquired similar advantageous variants. Functional studies on missense mutations involved in biallelic CD38 events revealed that 2 variants, L153H and C275Y, decreased binding affinity and antibody-dependent cellular cytotoxicity of the commercial antibodies daratumumab and isatuximab. However, a third mutation, R140G, conferred selective resistance to daratumumab, while retaining sensitivity to isatuximab. Clinically, patients with MM are often rechallenged with CD38 antibodies after disease progression and these data suggest that next-generation sequencing may play a role in subsequent treatment selection for a subset of patients.
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma
Claveau, Jean‐Sébastien , Kapoor, Prashant , Binder, Moritz , Buadi, Francis K. , Dingli, David , Fonder, Amie , Gertz, Morie A. , Hayman, Suzanne R. , Hobbs, Miriam, Christenson, Lisa Hwa, Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi, Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K , Dispenzieri, Angela , Fonder, Amie , Gertz, Morie A , Hwa Christenson, Yi Lisa, Kourelis, Taxiarchis , Lacy, Martha Q , Leung, Nelson , Warsame, Rahma , Kumar, Shaji K , Binder, Moritz , Dingli, David , Claveau, Jean-Sebastien , Dispenzieri, Angela , Gonsalves, Wilson I. , Christenson, Lisa Hwa, Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Journal | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2024027949 | PMID 40489635 Get It

Disease response and progression assessment in multiple myeloma (MM) is based on various measurements of monoclonal protein (serum and urine protein electrophoresis, serum free light chain (FLC, and or quantitative immunoglobulins). Currently, the IMWG consensus response criteria require two sequential assessments of any one marker made at any time before confirmation of disease progression and the institution of any new therapy. However, this can be cumbersome in clinical trials. Herein, we hypothesized that if two markers meet the progression criteria simultaneously, a repeat of either will not be necessary for confirmation. We retrospectively studied all sequential patients with myeloma enrolled in clinical trials at Mayo Clinic. We identified 583 episodes of confirmed progression in our study. Among the 583 progression episodes, nearly 70% (sensitivity of the simultaneous criteria) met the two simultaneous variable criteria at the first testing, indicating progression. Conversely, among 413 patients who met progression criteria by two simultaneous values, 98% (specificity of the simultaneous criteria) of patients subsequently had confirmed progression by sequential values. In summary, for patients with two disease burden markers meeting the simultaneous progression criteria, sequential assessment either one for confirmation may not be necessary to determine disease progression.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Avet‐Loiseau, Hervé , Davies, Faith E. , Samur, Mehmet , Corre, Jill , D’Agostino, Mattia , Kaiser, Martin , Raab, Marc S. , Weinhold, Niels , Gutiérrez, Norma C. , Paiva, Bruno , Walker, Brian A. , Bustoros, Mark , Stewart, A. Keith , Hillengaß, Jens , Martínez‐López, Joaquín , Sperling, Adam S. , Dhodapkar, Madhav V. , Spencer, Andrew , Parekh, Samir , Sonneveld, Pieter , Bergsagel, P. Leif , Orlowski, Robert Z. , Mateos, María‐Victoria , Kumar, Shaji , Munshi, Nikhil C. , Martinez-Lopez, Joaquin , Bergsagel, P. Leif , Samur, Mehmet K , Kaiser, Martin F , Weisel, Katja C , Maura, Francesco , Walker, Brian A , Bustoros, Mark , Stewart, A Keith , Usmani, Saad , Hillengass, Jens , Chng, Wee Joo , Keats, Jonathan J , Martinez-Lopez, Joaquin , Sperling, Adam S , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur S , Bolli, Niccolo' , Ghobrial, Irene M , Dhodapkar, Madhav V , Jagannath, Sundar , Spencer, Andrew , Parekh, Samir , Bahlis, Nizar Jacques , Sonneveld, Pieter , Orlowski, Robert Z. , Mateos, María-Victoria , San-Miguel, Jesus , Anderson, Kenneth C , Moreau, Philippe , Kumar, Shaji K , Munshi, Nikhil C , Raab, Marc S , Martinez-Lopez, Joaquin , Paiva, Bruno , Davies, Faith E , Corre, Jill , Mattia, D'Agostino , Neri, Paola , Maura, Francesco , Usmani, Saad Z. , Chng, Wee Joo , Keats, Jonathan J. , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur , Cavo, Michèle , Bolli, Niccolò , Ghobrial, Irene M. , Jagannath, Sundar , Lonial, Sagar , Morgan, Gareth J. , Rajkumar, S. Vincent , Miguel, Jesús F. San , Anderson, Kenneth C. , Moreau, Philippe , Prósper, Felipe

Mayo Clinic

Journal of Clinical Oncology | June 9, 2025 | Volume: 43 | Issue: 24 | Pages: 2739-2751

10.1200/jco-24-01893 | PMID 40489728 Get It

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
A comparative analysis of ARMS (anti-reflux mucosectomy) and TIF (transoral incisionless fundoplication) in the treatment of gastroesophageal reflux disease (GERD)
Sohail, Faryal, Saeed, Namra Asif, Jameel, Muhammad Usman , Assal, M. , Hasan, Zim Warda, Zafar, Arfah, Aminpoor, Hasibullah , Kumar, Vikash , Mohan, Anmol, Aminpoor, Hasibullah , Mohan, Anmol , Saeed, Namra Asif, Jameel, Maryam, Assal, Mazen W., Hasan, Zim Warda, Zafar, Arfah

Mayo Clinic

Annals of Medicine & Surgery | June 7, 2025 | Volume: 87 | Issue: 6 | Pages: 3596-3609

10.1097/ms9.0000000000003311 | PMID 40486585 Get It

Gastroesophageal reflux disease (GERD) is a prevalent condition impacting physical and mental health, characterized by symptoms like heartburn and acid regurgitation. GERD affects 18.1–27.8% of North Americans, rising to ~ 50% under less strict criteria. Effective management of GERD is critical to improving patients’ quality of life. Traditional treatments range from lifestyle modifications and pharmacological interventions to surgical approaches like laparoscopic anti-reflux surgery (LARS). Patients with erosive esophagitis receive a near 70–80% rate of “complete” symptom relief by 4 weeks using PPIs, in contrast to patients with non-erosive reflux disease (NERD), who demonstrate an intermediate response on the order of 50–60%. However, the invasiveness and associated side effects of surgical options have spurred the development of endoscopic techniques, including anti-reflux mucosectomy (ARMS) and transoral incisionless fundoplication (TIF). This review evaluates ARMS and TIF as therapeutic interventions for GERD, focusing on their risks, benefits, outcomes, and complications. ARMS is noted for shorter procedure times and fewer complications, particularly dysphagia and bleeding, making it an efficient choice for symptom control. TIF, while associated with a higher recurrence and reoperation rate, demonstrates superior long-term efficacy in medication reduction and sustained quality-of-life improvements, especially in patients without prior anti-reflux surgeries. Emerging advancements in endoscopic technologies, such as improved suturing techniques and refinements in mucosal resection, hold promise for reducing recurrence rates and enhancing procedural durability. The choice between ARMS and TIF should be tailored to individual patient needs, taking into account GERD severity, comorbidities, and surgical history. Both procedures exemplify significant advancements in minimally invasive GERD management, and ongoing innovations in endoscopic technologies are expected to further refine their safety and effectiveness. This comparative analysis provides insights into optimizing treatment selection and underscores the importance of personalized care in managing GERD.